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Acute kidney injury (AKI), a sudden deterioration in renal function which occurs when the 
kidneys no longer remove waste products from the blood, is a challenging medical condition 
that affects intensive care unit patients worldwide. Patients with severe cases of AKI are placed 
on renal replacement therapy (RRT), a life-supporting treatment, and have been linked to 
mortality rates as high as 60%. Despite having guidelines with indications for RRT it is unclear 
what the optimal initiation time should be. Studies looking at the association between timing of 
initiation and mortality give contradictory results: some suggest a better outcome with early 
initiation while others with late initiation. There are four issues with current studies: 1) 
selection bias due to treatment status being driven by a patient’s baseline characteristics and 
the physician’s decision to treat; 2) the time from which survival is measured is different across 
studies causing lead-time or immortal-time biases; 3) results from the different statistical 
methods used are not always comparable; 4) patients never started on RRT are excluded from 
analyses. 
The aim of this study is to determine the association between timing of initiation of RRT 
and mortality by addressing existing biases and limitations. Selection bias will be controlled for 
by a propensity score and 1-1 matching without replacement using the nearest neighbor 
Mahalanobis distance. Lead-time bias will be addressed by counting survival time from the 
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same point for all patients. Immortal-time bias will be eliminated by using an expanded risk sets 
analysis in which patients are part of all three risk groups: early, late, and no RRT. Unlike 
current studies patients never started on RRT will also be analyzed. Cox proportional hazards 
will be used to test differences in the hazard of mortality at 1-year between groups. 
Public Health Significance: To our knowledge, this is the largest observational study 
investigating the optimal time for initiating RRT.  Our study shows the effect of different biases 
on the outcome and reinforces the importance of carefully designing an observational study. 
Future nephrology researchers can use this work as foundation in the quest of finding the 
optimal time for RRT initiation. 
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1.0 INTRODUCTION 
Acute kidney injury (AKI) is a challenging condition characterized by an abrupt decline in kidney 
function over a period of hours to days that can occur before or in the hospital setting.1,2 
Worldwide, severe AKI occurs in approximately 6% of intensive care unit (ICU) patients, with 
almost two-thirds receiving renal replacement therapy (RRT).3 For severe AKI patients hospital 
mortality is approximately 60% and dialysis dependence at hospital discharge is approximately 
14%.3 AKI has also been associated with increased length of ICU and hospital stay, with those in 
need of RRT having a median ICU stay 3 times longer than those without AKI.1  
The association between timing of initiation of RRT and mortality is uncertain. The 
Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines recommend 
starting RRT based on the clinical context, the presence of conditions that can be modified with 
RRT, and trends of laboratory tests rather than single blood urea nitrogen or creatinine levels.2 
Despite these guidelines, hard data remain absent or conflictive regarding the optimal time to 
start dialysis.4 Some studies suggest that early initiation of RRT is associated with lower 
mortality5–8, other studies suggest no difference9,10, while a recent multicenter retrospective 
observational study found a U-shape association between RRT timing and in-hospital 
mortality.11 (Table 1) 
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Table 1: Summary of studies evaluating the timing of initiation of RRT 
Study Year Study Design N 
BUN 
at initiation of RRT (mg/dl) 
Hospital 
Mortality (%) 
Early Late Early Late 
Gettings et al.5 1999 Retrospective 100 <60 ≥60 61 80 
Demirkiliç et al.6 2004 Retrospectivea 61 NS NS 23.5 55.5 
Elahi et al.7 2004 Retrospectivea 64 67±35b 75±61b 22 43 
Liu et al.8  2006 Observational 243 ≤76 76 35c 41c 
Korevaar et al.9 2001 Prospectived 253 NS NS 16e 25e 
Bouman et al.10 2002 RCT 106 
LV: 48 (40-66)f 
HV: 46 (38-58)f 
LV: 
105 (62-116)f 
LV: 51 
HV: 37 
LV: 40 
Shiao et al.11 2012 Retrospectiveg 648 
EG: 49±29b 
IG: 59±26b 
LG: 90±43b 
EG: 59 
IG:49 
LG: 67 
a
RRT started based on urine output <100 ml over 8 hours in early group and based on biochemical parameters in 
late group. 
b
Mean BUN ± standard deviation. 
c
Percent of patients that died by day 28 from ICU admission. 
d
Classification into early and late was done according to the Dialysis Outcomes Quality Initiative
12
. 
e
Percent of
patients that died during the 24 months after RRT initiation. 
f
Median BUN (BUN quartiles). 
g
EG, early group, ≤1
day; IG, intermediate group, 2–3 days; LG, late group, ≥4 days between ICU admission and RRT initiation. BUN, 
serum blood urea nitrogen; RRT, renal replacement therapy; NS, not specified; RCT, randomized controlled trial; 
LV, low-volume hemofiltration; HV, high-volume hemofiltration; ICU, intensive care unit. 
1.1 SIGNIFICANCE 
There are four main shortcomings in current studies that attempt to define the optimal time for 
initiating RRT. First, there are absolute and relative indications for RRT initiation and the 
decision to start therapy is affected by strongly held physician beliefs, patient characteristics, 
and the logistical or organizational aspects of a given institution.13 The proportion of patients 
with absolute or relative indications may vary across studies leading to selection bias. Second, 
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the time from which survival is measured is not defined the same in all studies. Some studies 
measured survival from RRT initiation9,11, while others measured survival from a fixed time 
point prior to RRT initiation5–8,10 which causes lead-time bias and immortal-time bias 
respectively.  Suppose patient A starts RRT on the same day as KDIGO stage 3 (i.e. the baseline 
time point from which survival is measured), patient B starts RRT a few days after baseline and 
both patients are followed from their RRT initiation until death or censoring. In this case, 
patient A has an artificial survival advantage, or lead-time bias, since at the time of RRT 
initiation he/she was earlier in the course of disease progression than patient B (Figure 1 top). If 
both patients are followed from baseline until death or censoring patient B has an artificial 
survival advantage, or immortal-time bias, because he/she had to survive between baseline and 
RRT initiation (Figure 1 bottom). Third, the statistical methods used are different between 
studies and their results are not always directly comparable. In some studies the main outcome 
was the crude hospital mortality rate5–7 while other studies looked at time to event analyses.8–
11 Fourth, the exclusion from all current studies of patients that were never started on RRT due 
to recovery, death or lost to follow-up  severely limits their validity.14  
The aim of this study is to determine the association between timing of initiation of RRT 
and mortality by addressing the existing biases and limitations in the current literature. 
Treatment selection bias will be controlled for by the use of a propensity score15 and lead-time 
and immortal-time biases will be addressed by using an expanded risk sets (ERS) analysis.16 
Unlike current studies we will also take into account patients that were never started on RRT. 
4 
Figure 1: Illustration of lead-time bias and immortal-time bias 
RRT, renal replacement therapy; KDIGO stage 3 is the baseline time from which survival is measured. 
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2.0 MATERIALS AND METHODS 
2.1 STATISTICAL CONCEPTS 
2.1.1 Propensity Score in Observational Studies 
Estimating treatment effects in observational studies suffers from unmeasured confounding 
and selection bias due to treatment status being driven by a patient’s baseline characteristics 
and the physician’s decision to treat.  As a result, baseline characteristics differ systematically 
between treated and untreated subjects. Propensity score matching (PSM) methods are 
recommended in order to adjust for such unmeasured confounding and selection bias.17  
Per Rosenbaum and Rubin (1983) the propensity score is the probability towards 
treatment assignment conditional on observed baseline covariates. In practice, the propensity 
score is usually estimated by logistic regression: 
   
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. 
As such, the propensity score is a balancing score that allows the selection of treated (𝑡 = 1) 
and control (𝑡 = 0) subjects with similar distributions of observed baseline covariates, making 
the two groups directly comparable. 
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2.1.2 Mahalanobis Distance Matching 
Matching on the propensity score and any function of the observed baseline covariates will also 
balance the treatment and control groups.18 An implementation of this is the nearest available 
Mahalanobis distance which takes into account the variance and the covariance between all 
variables used in the calculation of distance. 
Let ix  be a vector of p observed baseline covariates for subject i  from the treatment 
group and jx  be a vector of p  observed baseline covariates for subject j  from the control 
group. Let   be the sample variance-covariance matrix, defined as: 
   
   
,
var cov ,
cov , var
i j
i i j
x x
i j j
x x x
x x x
 
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 
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. 
 Then, the Mahalanobis distance can be defined as: 
     
,
,
x xi j
T
d i j i jM i j x x x x
   1 . 
For uncorrelated variables with unit variance  ,dM i j  reduces to the Euclidean 
distance. Figure 2 provides an illustration of the Euclidean distance (a) and the Mahalanobis 
distance (b) where the contours represent equidistant points from the center using each 
distance metric.19 It can be seen that the Euclidean distance treats the data as if it had a 
spherical distribution while the Mahalanobis distance takes into account the distribution of the 
data points. 
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Figure 2: Illustration of Euclidean distance (a) and Mahalanobis distance (b)
Circles represent equal Euclidean distances towards the center point and ellipses represent equal Mahalanobis 
distances towards the center point.
19
Assuming that the propensity score has been generated, in order to calculate dM  and 
create a matched dataset, the following steps have to be taken: 
1. Transform the raw data X  through spectral decomposition of   into *X which 
has an identity covariance; 
2. Randomly order the subjects from the treatment group and those from the
control group; 
3. Calculate all pairwise Mahalanobis distances based on *X ; 
4. Choose the first subject i  from the treatment group and find subject j  from the
control group that has the smallest  ,dM i j ; 
5. Remove pair  ,i j  from the pool, move to the second subject from the
treatment group and apply steps 4 and 5 until there are no more subjects in the 
treatment group. 
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2.1.3 Cox Proportional Hazards Model 
For each i-th subject  1,...,ni   let *min( , )i i iT T C  be the observed follow-up time given by 
the minimum between the event time *
iT  and the censoring time iC ,  *i i iI T C    the event
indicator which is 1 when *
i iT C  and 0 otherwise, and iX  a vector of p baseline covariates. 
We are interested in estimating the marginal survival function at time t given by 
  ( )S t P T t   and adjusted for covariates X where the observed right-censored survival data 
will be represented by  , ,i i iT X  for each of the n subjects. In such a setting, Cox proportional 
hazards (PH) model is typically used.20  Cox PH is defined as: 
    '0|
Xh t X h t e  , 
where  0h t  is the unknown baseline hazard function for 0X   and   a p-dimensional vector 
of unknown parameters. The estimated marginal survival function under the Cox PH model is 
defined as: 
   
ˆ'
0
ˆˆ |
XH t e
S t X e

 , 
where ˆ   is the maximum-likelihood estimator of   and  0Hˆ t  is the Breslow estimator of
 0H t . This model is subject to the proportionality assumption which implies that the survival 
curves for different X  strata must have hazard functions that are proportional over time. 
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2.1.4 Expanded Risk Sets 
In order for the start of follow-up for survival to be the same for all RRT groups one would have 
to assign subjects to their RRT group on the day of KDIGO stage 3 which is impossible without 
knowing the future treatment path for each subject.  Suppose early RRT was defined as having 
started RRT within 3 days of KDIGO stage 3 and subject A started RRT on day 2 and died on day 
19, subject B started RRT on day 4 and was alive at one year, subject C never started RRT and 
died on day 4 and subject D never started RRT and was alive at one year. In retrospect we 
would say that subject A was an early starter, subject B a late starter and subjects C and D were 
part of the no RRT group. However, following the subjects prospectively it is not until days 2, 4, 
4, and one year that we know the true groups for subjects A, B, C, and D respectively. Thus the 
true RRT group is determined after the start of follow-up and it is contrived to assign subjects to 
a group on the day of KDIGO stage 3. 
Through the use of ERS analysis subjects are followed prospectively from the time they 
reach KDIGO stage 3 and are allowed to have different contributions of follow-up times and 
events in all three risk sets: early RRT, late RRT, and no RRT. Figure 3 displays the ERS replicate 
contributions for subjects A, B, C, and D. For example, subject A was followed in the early RRT 
group for 19 days and contributed with an event to this group.  Subject A also had the potential 
of being part of the late RRT and no RRT groups for 2 days until he/she was artificially censored 
because RRT was initiated. Subject B had the potential to be part of the early RRT group for 3 
days and was censored, was followed in the late RRT group for one year and was censored, and 
had the potential to be part of the no RRT group for 4 days, until RRT was initiated, and as a 
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result became censored. Subject C had the potential to be part of the early RRT group for 3 days 
and was censored, was followed in the late RRT and no RRT groups for 4 days, until his/her 
death. Thus he/she contributed with an event to both late and no RRT groups. Subject D had 
the potential to be part of the early RRT group for 3 days, was followed in the late RRT and no 
RRT groups for one year and did not contribute with an event to any of the three groups. 
Figure 3: Follow-up of subjects from different RRT groups in the expanded risk sets
See section 2.1.4 for a detailed explanation. RRT, renal replacement therapy; KDIGO stage 3 is the baseline 
time from which survival is measured. 
A survival analysis based on the ERS does not suffer from lead-time bias or immortal-
time bias.16 Lead-time bias is prevented by starting the follow-up time for survival from KDIGO 
stage 3 for all subjects. Immortal-time bias is prevented by not defining the RRT group using the 
follow-up time21 and also by not excluding subjects who die or become censored before they 
start RRT.16 
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2.2 TIMING OF RRT STUDY DATA 
2.2.1 Study Population 
This retrospective cohort study used the High-Density Intensive Care (HiDenIC-8) database, 
which includes data on a source population of 45,568 adult patients admitted to one of 8 ICUs 
(i.e. medical, cardiac, transplant, surgical, neurological and trauma) within a single academic 
medical center (University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA) during an 8-
year period (July 2000 through October 2008). HiDenIC-8 data was obtained from several 
computerized databases and deidentified using an honest broker as previously described.22  
For this study, we selected a population of patients that reached KDIGO stage 3 during their 
hospital stay and: 1) had no prior history of hemodialysis or renal transplant; 2) their known 
baseline creatinine was < 4; 3) had no liver transplant during hospitalization; 4) had no history 
of heart failure. We were able to identify 4781 such patients. Furthermore, in order to ensure 
that the population selected had a comparable risk of being started on RRT we  applied the 
following exclusions: 1) RRT started within 24 hours from ICU admission (n=199); 2) in the 
group of patients that did not receive RRT an increase in serum creatinine (sCr) within 48 hours 
from KDIGO stage 3 was not observed (n=1860); 3) KDIGO stage was classified on urine output 
(UO) only and the previous rule could not be determined (n=121); 4) no data on risk factors of 
interest (n=676).  The remaining 1925 patients formed our study population (Figure 4).  This 
study was conducted in accordance with institutional review board guidelines and approval. 
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Source Population 
(n = 4781)
 RRT started before 24 hours from ICU admission (n = 199 )
 Within the no RRT group there was not an increase in 
creatinine within 48 hours from KDIGO Stage 3 (n = 1860)
 AKI was based only on urine output and previous criterion
could not be determined  (n = 121)
 Missing data on covariates (n = 676)
Study Population  
(n = 1925; 40.3%)
No RRT       
(n = 1017; 52.8%)
RRT           
(n = 908; 47.2%)
Figure 4: Study population
RRT, renal replacement therapy; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global 
Outcomes; AKI, acute kidney injury.  
2.2.2 Data Collection 
Data variables included demographic data, comorbid conditions, and indications for RRT. 
Demographic data consisted of age, sex and race. History of cardiac disease, chronic renal 
disease, diabetes and liver transplant were considered. Reference creatinine was derived as 
previously described.22 Admission type (medical versus surgical) was based on the diagnosis 
related group at hospital admission. Biochemistry data such as  sCr, fraction of inspired oxygen 
(FiO2), serum potassium (sK
+), serum bicarbonate (HCO3) and serum blood urea nitrogen (BUN) 
were extracted. Severity scores included Glasgow Coma Scale (GCS), APS-III score and severity 
of hypotension. Fluids infused, weight adjusted urine, suspected sepsis, use of vasopressors and 
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mechanical ventilation support were also considered. All variables were measured in the 24 
hours following ICU admission and their definitions have been previously described.22  
Patients were classified according to their maximum KDIGO criteria met during 
hospitalization using sCr and UO criteria.2 If multiple episodes of KDIGO stage 3 occurred we 
only considered the first one as our entry criteria. 
2.2.3 Timing of RRT 
The first instance of intermittent hemodialysis or continuous RRT was considered as the time of 
initiation of RRT. Early RRT was defined based on the number of calendar days from KDIGO 
stage 3 to initiation of RRT. The definition varied from 1 to 7 days. Patients that were started on 
RRT later than the cut off day or those that were never started on RRT during their 
hospitalization were used as the control group. 
2.2.4 Outcome Assessment 
The primary end point of this study was 1-year mortality from KDIGO stage 3. The survival 
period was calculated from KDIGO stage 3 to mortality (in non-survivors) or censored at 1-year 
(in survivors). 
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2.2.5 Statistical Analyses 
Statistical analyses were performed using STATA (version SE 11.2), with statistical significance 
set at p-value <0.05. Mahalanobis matching was done in SAS (version 9.3).  Graphs were 
created in Microsoft Excel 2010 unless otherwise specified. Categorical variables were 
summarized as frequency (percentage) and continuous variables were summarized as 
median±interquartile range. For categorical variables the Pearson Chi-square asymptotic test 
was used and for continuous variables the Kruskal Wallis  test was used.  First, to determine the 
propensity for early RRT we ran multivariable logistic models with all risk factors from Table 2. 
All variables were retained in the model regardless of significance level. For a sensitivity 
analysis, however, backward stepwise selection was used with the probability-to-enter set at 
0.05 and probability-to-remove set at 0.1. In this procedure, removal testing was based on the 
probability of the likelihood-ratio statistic based on conditional parameter estimates. Second, 
matches from the pool of late/no RRT patients were chosen without replacement using a 1-1 
nearest neighbor Mahalanobis distance algorithm. The propensity for early RRT from the 
logistic regression along with the reference creatinine, FiO2, sK
+, fluids and weight adjusted
urine were used in calculating the Mahalanobis distance. Covariate balance between groups 
was checked by plotting the chi-square statistics from the unmatched and matched 
populations. Third, the ERS method was applied to the unmatched and to the matched 
populations. We used Cox proportional hazards regression adjusted for age to test the 
differences in the hazard of mortality at 1-year between late RRT versus early RRT and between 
no RRT versus early RRT. All steps were applied to each of the 7 populations from Table 3. 
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3.0 RESULTS 
3.1 BASELINE CHARACTERISTICS 
Of the 1925 patients meeting the inclusion criteria, 47.2% were started on RRT after reaching 
KDIGO stage 3. Baseline characteristics for the RRT and no RRT groups are shown in Table 2. As 
expected, younger patients, liver transplants, multiple comorbidities, higher reference 
creatinine, surgical admission, higher FiO2, azotemia (BUN ≥ 100), worse APS-III scores, more 
fluids, lower weight adjusted urine, suspected sepsis and use of vasopressors were more 
common in the RRT group (p-values 0.03 to <0.001). There was no difference in hyperkalemia 
(sK+ > 5 meq/L) (p-value 0.12). 
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Table 2: Patient characteristics by in-hospital RRT 
Characteristics 
RRT No RRT All 
P-value* 
(N = 908) (N = 1017) (N = 1925) 
Age 60 (49-70) 64 (51-76) 62 (50-73) <0.001 
Males 526 (57.9) 544 (53.5) 1,070 (55.6) 0.05 
Race 
0.79 
  White 682 (75.1) 750 (73.7) 1,432 (74.4) 
  Black 58 (6.4) 68 (6.7) 126 (6.5) 
  Other 168 (18.5) 199 (19.6) 367 (19.1) 
Comorbid condition 
Cardiac disease 35 (3.9) 47 (4.6) 82 (4.3) 0.41 
Chronic renal disease 53 (5.8) 46 (4.5) 99 (5.1) 0.19 
Diabetes 137 (15.1) 158 (15.5) 295 (15.3) 0.79 
Liver transplant 59 (6.5) 39 (3.8) 98 (5.1) 0.008 
Multiple comorbidities 396 (43.6) 394 (38.7) 790 (41) 0.03 
Reference creatinine, mg/dl 1 (0.8-1.2) 0.9 (0.8-1.1) 1 (0.8-1.1) <0.001 
Surgical admission 577 (63.5) 568 (55.9) 1,145 (59.5) 0.001 
sCr ≥ 4 meq/La 152 (16.7) 154 (15.1) 306 (15.9) 0.34 
FiO2 > 60%
a 258 (28.4) 240 (23.6) 498 (25.9) 0.02 
sK+ > 5 meq/La 188 (20.7) 182 (17.9) 370 (19.2) 0.12 
HCO3 < 18 meq/L
a 82 (9) 73 (7.2) 155 (8.1) 0.14 
BUN ≥ 100 mgs/dla 44 (4.8) 29 (2.9) 73 (3.8) 0.02 
GCSa 
0.36 
[3,5] 234 (25.8) 250 (24.6) 484 (25.1) 
[6,10] 281 (30.9) 294 (28.9) 575 (29.9) 
[11,15] 393 (43.3) 473 (46.5) 866 (45) 
APS-III scorea 87 (67-112) 79 (59-103.5) 83 (62-109) <0.001 
Severity of hypotensiona,b 1.5 (0-15.1) 0.5 (0-13) 1 (0-14) 0.05 
Fluids, La 4.4 (2.7-6.9) 3.7 (2.3-6.1) 4 (2.5-6.5) <0.001 
Weight adjusted urine, CCsa 11.3 (4.5-20.3) 13.1 (7.2-23) 12.3 (5.9-21.4) <0.001 
Suspected sepsisa 303 (33.4) 219 (21.5) 522 (27.1) <0.001 
Vasopressorsa 430 (47.4) 411 (40.4) 841 (43.7) 0.002 
Mechanical ventilationa 604 (66.5) 649 (63.8) 1,253 (65.1) 0.21 
Data presented as n (%) or median (Q1-Q3). RRT, renal replacement therapy; sCr, serum creatinine;  FiO2, fraction of inspired 
oxygen; sK+, serum potassium; HCO3, serum bicarbonate; BUN, serum blood urea nitrogen; GCS, Glasgow Coma Scale; APS-III,
acute physiology score.  
*P-va lue for the comparison of RRT and No RRT. For categorical variables Pearson Chi-square asymptotic 2-sided test was used. 
For continuous variables Kruskal Wallis Test was used.  
a
Measured within 24 hours following ICU admission.  
b
Area under the curve for severity and duration of hypotension.  
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3.2 MATCHING 
3.2.1 Generating Propensity Scores 
For this study we used the days from KDIGO stage 3 to RRT initiation [median (interquartile 
range): 3 (2-7)] to define early RRT. We had no a priori definition for the number of days that 
should classify patients as early starters. Instead, we looked at various cut off points where 
early was defined as having started RRT on the same day as KDIGO stage 3 or anywhere up to 
and including day 7. As seen in Table 3 under the unmatched analysis (i.e. the study 
population), in population 1 there were 192 patients that started RRT on the same day as 
KDIGO stage 3, 716 that started RRT anywhere after day 2 and 1017 that were never on RRT for 
a total of 1925 patients. In population 2, there were 128 more patients that started RRT on day 
2, thus the early group had 320 patients while the late group was left with 588. 
We used the same logistic regression model to generate the propensity for early RRT for 
each of the 7 unmatched populations: 
  
 
 
|
logit | log
|
i i
i i i
i i
P Y X
P Y X X
P Y X
 
  
    
  
0 1
1
1
0
, 
where 
Y = 1 for early RRT, 
Y = 0 for the combined late and no RRT groups, 
X = vector of all baseline covariates from Table 2. 
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Table 3: Sample size description by early RRT definition and analysis type 
Days from KDIGO 
Stage 3 to RRT 
Initiation 
Unmatched Analysis* Matched Analysis^ ERS Analysis# 
(n) Early RRT 
(n) 
Late RRT 
(n) 
No RRT 
(n) 
Late RRT 
(n) 
No RRT 
(n) 
Population 1: 1 192 716 1017 76 116 1152 
Population 2: ≤ 2 320 588 1017 139 181 1920 
Population 3: ≤ 3 470 438 1017 161 309 2820 
Population 4: ≤ 4 568 340 1017 161 407 3408 
Population 5: ≤ 5 636 272 1017 147 489 3816 
Population 6: ≤ 6 673 235 1017 150 523 4038 
Population 7: ≤ 7 703 205 1017 133 570 4218 
* Early RRT + Late RRT = 908 and Early RRT + Late RRT + No RRT = 1925 regardless of population.
^ Late RRT + No RRT = Early RRT; under each matched population, the numbers in the late and no RRT groups represent the
number of  matched patients from the available pool of unmatched patients in the late and no RRT  groups. 
# Early RRT + (Late RRT + No RRT)^ multiplied by 3 wi ll give the ERS (n).
3.2.2 Generating Matched Populations 
For each population from Table 3 each subject i  from the early RRT group was matched 
without replacement to one subject j  from the late or no RRT group by using the nearest 
neighbor Mahalanobis distance algorithm.  The propensity for early RRT and the following 
baseline covariates, identified a prior as being clinical indicators for RRT initiation, were used in 
calculating all 'sdM for each  ,i j  pair: reference creatinine, FiO2, sK
+, fluids and the weight
adjusted urine. Table 3, under the matched analysis, gives the number of matched patients and 
the group from which they originated. For example, in population 1 all 192 patients from the 
early RRT group were matched to 76 out of 716 and 116 out of 1017 patients from the available 
late and no RRT groups respectively. 
For each population, we checked the distribution and common support of the 
propensity scores between the early RRT group and the matched and unmatched late and no 
RRT groups. Figure 5 shows adequate overlap in the propensity scores between the early RRT 
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group and the matched late and no RRT groups. In other words, each late and no RRT patient 
had a good match on the propensity score to an early RRT patient. Population 7 not shown but 
the results were similar. 
We also checked the balance before and after matching on all baseline risk factors that 
were used to generate the propensity for early RRT. Figure 6 displays a plot of the chi-square 
statistics for the test of difference in risk factors between early RRT and the combined late and 
no RRT groups before matching (red) and after matching (green). For categorical variables we 
used the Pearson chi-square statistic23 
n
i i
i k
i i
O N p
N p
p
 

 
  
 

2
2 2
1
, 
where 
N  = the total number of observations, 
n  = the number of cells compared, 
ip  = the proportion of observations of type i , 
iO  = the number of observations of type i , 
k
2  = chi-square distribution with k degrees of freedom. 
For continuous variables we used the Kruskal-Wallis statistic24 
 
     
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 
 
      
  
 
2
3 3 2
1
1 1
12
3 1 1
1 , 
where 
c  = the number of samples, 
in  = the number of observations in sample i , 
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N  = in , the number of observations in all samples combined,
iR  = the sum of the ranks in sample i , 
g  = the number of groups with tied observations, 
jt   = the number of tied observations in group j , 
c 
2
1 = chi-square distribution with c1degrees of freedom. 
The central tendency line (gray) represents the chi-square value of 3.84 which is analogous to a 
p-value of 0.05 for a chi-square distribution with 1 degree of freedom. Before matching, across 
all populations, there was imbalance in most risk factors as represented by the red symbols 
associated with high chi-square values. However, after matching, the imbalance between risk 
factors was corrected as represented by the green symbols with very low chi-square values 
(Figure 6). 
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Figure 5: Jitter plot of propensity scores in the matched and unmatched groups
Matches chosen without replacement using a 1 -1 nearest neighbor Mahalanobis distance algorithm on the propensity for early RRT, reference    creatinine, FiO 2, 
sK
+
, fluids and weight adjusted urine.
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= 𝟑. 𝟖𝟒) except for Race and GCS which had 2 (𝝌𝟐
𝟐
,𝟎.𝟎𝟓 =
Figure 6: Covariate balance before and after matching 
All tests had 1 degree of freedom (𝝌𝟏
𝟐
,𝟎.𝟎𝟓                                                                                                                                                                                                       𝟓. 𝟗𝟗). For a detailed explanation see section 3.2.2. 
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3.2.3 Generating Expanded Risk Sets Populations 
For the ERS analysis, patients from each matched population were allowed to have different 
contributions of follow-up times and events in all three risk sets: early RRT, late RRT, and no 
RRT. As a result, the ERS analysis population will have 3 times more subjects than the 
corresponding matched population. For example, population 1 had 192*2=384 subjects in the 
matched analysis and 384*3=1152 in the ERS analysis (Table 3). 
3.3 SURVIVAL 
3.3.1 Before Matching 
In the unmatched populations, unadjusted analyses showed no difference in hospital mortal ity 
between early and late starters except for population 5, where late starters had higher hospital 
mortality than early starters: 62.9% vs 54.1% (p-value 0.01) (Table 4). The unadjusted 1-year 
mortality was significantly worse in late than in early starters as the definition for early RRT 
changed from ≤3 to ≤7 days (Table 4). There was no apparent benefit in initiating RRT earlier in 
the course of the disease progression since the 1-year mortality in the early group only slightly 
increased from 66.9% in population 2 to 68.8% in population 7.  However, these results suffer 
from selection bias and immortal-time bias. 
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Table 4: Unadjusted outcomes before matching 
Early RRT 
Hospital Mortality (%) 1-year Mortality (%) 
Early RRT Late RRT  No RRT P-value* Early RRT Late RRT  No RRT P-value* 
Population 1 59.4 56 
41.3 
0.4 69.8 70.9 
57.7 
0.75 
Population 2 55.6 57.3 0.62 66.9 72.8 0.06 
Population 3 55.3 58.2 0.38 67.2 74.4 0.02 
Population 4 54.2 60.9 0.05 67.8 75.6 0.01 
Population 5 54.1 62.9 0.01 67.9 77.2 0.005 
Population 6 54.8 62.1 0.05 68.8 76.2 0.03 
Population 7 55.2 62 0.09 68.8 77.1 0.02 
The sample size for each population and RRT group is the same as in Table 3 under the unmatched analysis. 
*P-value for the comparison between early RRT and late RRT groups only. 
All  3-way comparisons had p-value <0.001. 
In the unmatched populations, after adjusting for age and taking into account the time 
to death there was no difference in the hazard of mortality at 1-year between early and late 
starters (Figure 7a). Even though the hazard ratio (HR) in population 1 (HR (95%CI): 0.86 (0.71-
1.04)) seemed to favor late initiation the confidence interval contained 1. As definitions for 
early RRT changed the HRs got very close to 1 and there was no clear signal of an optimal time 
for initiation. However, these results suffer from both selection bias and immortal -time bias. 
Next, we removed the artificial survival advantage given to late starters by applying the 
ERS method to the unmatched populations. The sample size for each population was 5775 
(1925*3). In this analysis, there seems to be an advantage in delaying RRT since the rate of 
mortality for the late RRT group decreased from 14% in population 2 to 25% in population 7 
(Figure 7b). Selection bias has not been addressed in the ERS analysis on the unmatched 
populations. 
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Figure 7: Age adjusted survival at 1-year before matching 
Red dots represent the hazard ratios (HR) for late RRT vs early RRT; black lines represent 95% confidence intervals for 
HR; dashed lines represent a HR of 1; ERS, expanded risk sets. Sample size for each population in (a) is 1925. Sample 
size for each population in (b) is 1925*3=5775. 
3.3.2 After Matching 
In the matched analysis, after controlling for age, there was no difference in the hazard of 
mortality at 1-year associated with timing of RRT initiation. Even though in population 1 the HR 
of 0.84 seemed to favor late initiation the 95% confidence interval (0.61-1.16) contained 1 
(Table 5). As definitions for early RRT changed the HRs got very close to 1 and there was no 
clear signal of an optimal time for initiation. Except for populations 2 and 5 patients that were 
never started on RRT seemed to have a decreased hazard of 1-year mortality when compared 
to early starters (Table 5). However, these results still suffer from immortal-time bias. 
In the ERS analysis the HRs were lower for both late and no RRT groups but their 
magnitude did not change with the varying definitions for early RRT. In population 1 the rate of 
mortality decreased by 25% in the late RRT group and by 44% in the no RRT group. When the 
definition of early RRT was changed, the rates of mortality in the late RRT group only slightly 
varied from 24% in population 3 to 27% in population 7 with no significant decrease in mortality 
for population 2. Similar to the results seen in Figure 7b which only suffered from selection 
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bias, there seems to be an advantage in delaying RRT once both selection bias and immortal -
time bias were removed through the use of the ERS analysis. 
Table 5: Survival at 1-year in the matched and expanded risk sets populations 
Matched Analysis ERS Analysis 
Early RRT 
N 
HR* (95%CI) 
N 
HR* (95%CI) 
Late vs Early No RRT vs Early Late vs Early No RRT vs Early 
Population 1 384 0.84 (0.61-1.16) 0.71 (0.53-0.96) 1152 0.75 (0.59-0.96) 0.56 (0.42-0.76) 
Population 2 640 0.93 (0.73-1.18) 0.85 (0.67-1.07) 1920 0.85 (0.71-1.03) 0.63 (0.5-0.79) 
Population 3 940 0.88 (0.71-1.09) 0.78 (0.65-0.94) 2820 0.76 (0.65-0.89) 0.59 (0.49-0.71) 
Population 4 1136 0.99 (0.8-1.22) 0.8 (0.68-0.94) 3408 0.78 (0.67-0.88) 0.6 (0.52-0.71) 
Population 5 1272 0.92 (0.74-1.13) 0.87 (0.75-1.01) 3816 0.77 (0.67-0.87) 0.64 (0.55-0.73) 
Population 6 1346 0.93 (0.75-1.15) 0.81 (0.7-0.94) 4038 0.73 (0.65-0.83) 0.6 (0.53-0.69) 
Population 7 1406 0.96 (0.77-1.19) 0.83 (0.72-0.95) 4218 0.73 (0.65-0.83) 0.61 (0.54-0.7) 
RRT, renal replacement therapy; HR, hazard ratio; CI, confidence interval; ERS, expanded risk sets; *Age adjusted. 
For a sensitivity analysis we determined the propensity for early RRT by using 
multivariable logistic regression with backward stepwise variable selection as described under 
section 2.2.5. We then followed all other steps for matching and for creating ERS populations. 
Changing the method for selecting the propensity for early RRT did not modify our overall 
results. There still seems to be an advantage in delaying RRT once both selection bias and 
immortal-time bias were removed through the use of the ERS analysis (Figure 8a). 
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Figure 8: Age adjusted survival at 1-year after matching 
Red dots represent the hazard ratios (HR) for late RRT vs early RRT (a) and for no RRT vs early RRT (b); black lines 
represent 95% confidence intervals for HR; dashed lines represent a HR of 1; ERS, expanded risk sets. Populations 
were generated from ERS models based on matched populations where the propensity for early RRT was modeled 
with a backward stepwise selection method. The sample size for each population is the same as in the ERS analysis 
from Table 3 but the sample size for the true late and true no RRT groups is slightly different. 
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4.0 DISCUSSION 
In this retrospective cohort study, using a large adult population admitted to one of 8 ICUs 
within a single academic medical center over an 8-year period, we examined the association 
between timing of initiation of RRT and 1-year mortality. Current studies in this domain suffer 
from either selection bias, lead-time bias, and/or immortal-time bias. To our knowledge, in the 
renal literature, there is only one other study that addresses both lead-time bias and immortal-
time bias.16 However, there are several major differences between our studies. First, we 
defined the groups early RRT, late RRT, and no RRT based on the number of days from KDIGO 
stage 3 to RRT initiation (Table 3) and not on changes in estimated glomerular filtration rate. 
Second, we varied our definition for early RRT from 1 to 7 days to find the optimal time for RRT 
initiation. Third, before expanding the risk sets we dealt with selection bias. In conclusion, by 
using a new definition for the timing of initiation and statistical techniques based on propensity 
scores, Mahalanobis matching, and ERS analyses we have addressed three of the existing biases 
in the current literature. 
In randomized control trials, on average, patients are similar on all baseline 
characteristics. Hence, any significant differences between groups in the outcome event can be 
attributed to the intervention.25 However, in observational studies, the assignment of patients 
into the treatment and control groups is typically not random. Differences in the outcome may 
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not necessarily be due to the treatment effect but rather to the differential distributions of 
other prognostic factors, known and unknown, which are associated with both the outcome 
and the decision to treat.26–28 We believe that our study contains patients in the late RRT and 
no RRT groups in which due to their baseline risk factors and day-to-day disease progression 
the decision to initiate RRT was never a choice. This is supported by the divergent distributions 
of risk factors between the early RRT and late/no RRT groups (Figure 6). Even though with the 
available risk factors we cannot address the daily changes in a patient’s risk to be initiated on 
RRT, we believe that the spectrum of their baseline risk factors is a good indication for the 
decisions made. Although no method can be trusted to remove hidden selection bias,  it is 
important to minimize differences between known risk factors .26 Thus, as suggested in 
literature, the use of a propensity score along with Mahalanobis metric matching can eliminate 
hidden selection bias.18,29,30  
Lead-time bias occurs in observational studies when follow-up time for survival is 
counted from the exposure time rather than from enrollment. Patients exposed to the 
treatment earlier in the course of their disease development get an artificial survival time over 
those that are exposed later. Even though it has been acknowledged as a limitation by several 
authors9,31,32 dating to 2001, studies affected by this bias have been published in 201033 and as 
recently as 201434. In our study, survival time was counted from the time patients reached the 
same severity in their renal dysfunction, namely KDIGO stage 3. 
Immortal time in epidemiology refers to a period of cohort follow-up or observation 
time, during which death cannot occur.35 Depending on the methodology used, if immortal 
time is not correctly accounted for, estimated treatment effects can be substantially biased. 36 
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Pharmacoepidemiology research has shown that for time-based, event-based, and exposure-
based cohort definitions, the bias in the rate ratio resulting from misclassified or excluded 
immortal time increases proportionately to the duration of immortal time.37,38 A review of 127 
studies published in highly-cited medical journals found that immortal time was not handled 
properly in 52 of them.39  
Immortal time bias can occur in observational studies in one of two ways. The first is 
through misclassification of immortal time as a part of the follow-up time for survival. As a 
result, patients with longer immortal time periods have an artificially inflated survival 
advantage when compared to patients with shorter immortal time periods. The second is 
through exclusion of immortal time from the analysis and then starting the follow-up time for 
survival at the exposure time.  Immortal time bias through exclusion differs from lead-time bias 
in that in occurs when patients who were never exposed to the treatment of interest are now 
included in the survival analysis. In this case, the exposed and unexposed patients are not 
comparable because their follow-up times start at different stages in the development of their 
disease. In the ERS analysis the RRT group assignment is made at baseline ( i.e. KDIGO stage 3) 
thus the time-varying nature of the treatment is removed and patients no longer have immortal 
time. For example, within the early RRT group, subjects that initiated RRT or those that died or 
become censored before initiating RRT all contribute their observed follow-up days for survival 
to the same treatment regime – early RRT, thus within group  immortal-time bias has been 
removed. 
There are important limitations to our study. First, because this was an observational 
study our results are subject to unmeasured confounding ( i.e. hidden bias) and causation 
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cannot be established. Even though we used a propensity score to minimize selection bias, we 
only used patient specific parameters to address this issue and there are immeasurable 
physician beliefs and logistical and/or operational issues that impact RRT initiation that we did 
not account for.13  Second, even though we had a large sample size, patients are all from a 
single medical center which makes it difficult to assess the generalizability of our results. 
However, we had access to patient data from multiple ICUs ( i.e. medical, cardiac, transplant, 
surgical, neurologic, and trauma) which increases our confidence that the results are not 
unique to this medical center. Third, by using the ERS method we introduced nonrandom 
censoring and patients censored at time t  will have worse prognosis than uncensored 
patients.16 In the future, we plan to use inverse probability weighting to adjust for any new 
selection bias introduced by the nonrandom censoring.16,40  
In this study, we found that selection bias did not have a big impact on the estimated 
hazard of mortality but immortal-time bias drastically affected the conclusions drawn. When 
comparing results from unmatched and matched analyses that still suffered from immortal-
time bias we concluded that there was no clear signal of an optimal time to initiate RRT (Figure 
7a versus Table 5 - matched analyses). However, after removing immortal-time bias, regardless 
of selection bias, there seemed to be an advantage in delaying RRT (Figure 7b and Table 5 - ERS 
analysis). 
In conclusion, the optimal time to start dialysis is still uncertain but we believe that 
building upon our methods and those used by Sjolander et al.16 will aid future researchers in 
better analyzing observational data and providing less biased estimates. 
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